1. Three weekly versus weekly concurrent cisplatin: safety propensity score analysis on 166 head and neck cancer patients
- Author
-
Michela Buglione, Daniela Alterio, Marta Maddalo, Diana Greco, Marianna Alessandra Gerardi, Davide Tomasini, Ludovica Pegurri, Matteo Augugliaro, Giulia Marvaso, Irene Turturici, Andrea Guerini, Mohssen Ansarin, Luigi Spiazzi, Loredana Costa, Maria Cossu Rocca, Stefano Maria Magrini, and Barbara Alicja Jereczek-Fossa
- Subjects
H&N cancer ,Radiotherapy ,Chemotherapy ,Weekly-CDDP ,3weekly-CDDP ,Medical physics. Medical radiology. Nuclear medicine ,R895-920 ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background Radio-chemotherapy with CDDP is the standard for H&N squamous cell cancer. CDDP 100 mg/m2/q3 is the standard; alternative schedules are used to reduce toxicity, mostly 40 mg/m2/q1. Methods Patients were treated from 1/2010 to 1/2017 in two Radiation Oncology Centres. Propensity score analysis (PS) was retrospectively used to compare these two schedules. Results Patients analyzed were 166. Most (114/166) had 1w-CDDP while 52 had 3w-CDDP. In the 3w-CDDP group, patients were younger, with better performance status, smaller disease extent and a more common nodal involvement than in the 1w-CDDP. Acute toxicity was similar in the groups. Treatment compliance was lower in the w-CCDP. Overall survival before PS was better for female, for oropharyngeal disease and for 3w-CDDP group. After PS, survival was not related to the CDDP schedule. Conclusions 3w-CDDP remains the standard for fit patients, weekly schedule could be safely used in selected patients.
- Published
- 2021
- Full Text
- View/download PDF